A detailed history of Hrt Financial LP transactions in Arvinas, Inc. stock. As of the latest transaction made, Hrt Financial LP holds 43,445 shares of ARVN stock, worth $813,724. This represents 0.01% of its overall portfolio holdings.

Number of Shares
43,445
Holding current value
$813,724
% of portfolio
0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$23.66 - $32.73 $1.03 Million - $1.42 Million
43,445 New
43,445 $1.07 Million
Q4 2023

Feb 09, 2024

BUY
$14.19 - $42.33 $259,293 - $773,496
18,273 New
18,273 $752,000
Q3 2022

Nov 14, 2022

BUY
$41.87 - $57.99 $2.27 Million - $3.14 Million
54,102 Added 349.72%
69,572 $3.1 Million
Q2 2022

Aug 12, 2022

BUY
$36.01 - $74.24 $310,442 - $640,023
8,621 Added 125.87%
15,470 $651,000
Q1 2022

May 16, 2022

BUY
$60.27 - $81.57 $412,789 - $558,672
6,849 New
6,849 $460,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $997M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.